Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications
Bio-Techne (NASDAQ: TECH) announced advancements in its spatial biology portfolio, featuring the RNAscope™ ISH technology and Lunaphore COMET™ platforms. These innovations enable simultaneous detection of RNA and protein biomarkers on the same tissue section, bridging translational research and clinical applications.
The company will showcase these technologies at the National Society of Histotechnology Convention (September 26-30), featuring presentations on RNAscope's application in B-cell clonality assessment and COMET's capabilities in lymphoid malignancy profiling using a 21-plex seqIF™ panel. Bio-Techne is also advancing its partnership with Leica Biosystems, co-hosting a reception to demonstrate RNAscope assays on Leica BOND platforms.
Bio-Techne (NASDAQ: TECH) ha annunciato avanzamenti nel proprio portafoglio di biologia spaziale, includendo la tecnologia RNAscope™ ISH e le piattaforme Lunaphore COMET™. Queste innovazioni consentono la rilevazione contemporanea di biomarcatori di RNA e proteine sulla stessa sezione tissutale, collegando la ricerca traslazionale alle applicazioni cliniche.
L’azienda presenterà queste tecnologie al National Society of Histotechnology Convention (26-30 settembre), con interventi sull’uso di RNAscope per la valutazione della clonality delle cellule B e sulle capacità di COMET nel profilare neoplasie linfoidi utilizzando un pannello 21-plex seqIF™. Bio-Techne sta inoltre rafforzando la partnership con Leica Biosystems, co-organizzando una reception per mostrare gli assay RNAscope sulle piattaforme Leica BOND.
Bio-Techne (NASDAQ: TECH) anunció avances en su cartera de biología espacial, destacando la tecnología RNAscope™ ISH y las plataformas Lunaphore COMET™. Estas innovaciones permiten la detección simultánea de biomarcadores de ARN y proteínas en la misma sección tisular, uniendo la investigación translacional con aplicaciones clínicas.
La empresa mostrará estas tecnologías en la Convención de la National Society of Histotechnology (26-30 de septiembre), con presentaciones sobre la aplicación de RNAscope para evaluar la clonalidad de células B y las capacidades de COMET para perfilar malignidades linfoides usando un panel seqIF™ de 21 pliegues. Bio-Techne también está fortaleciendo su alianza con Leica Biosystems, coorganizando una recepción para demostrar ensayos de RNAscope en las plataformas Leica BOND.
Bio-Techne (NASDAQ: TECH)가 공간생물학 포트폴리오의 진전을 발표했습니다. RNAscope™ ISH 기술과 Lunaphore COMET™ 플랫폼이 포함됩니다. 이러한 혁신은 동일한 조직 표본에서 RNA 및 단백질 바이오마커를 동시 검출할 수 있게 하여 번역 연구와 임상 적용을 이어 줍니다.
회사는 이것들을 National Society of Histotechnology Convention에서 9월 26–30일에 선보이고, RNAscope의 B-세포 클로날성 평가 적용과 21-plex seqIF™ 패널을 이용한 림포이드 악성종양 프로파일링에서의 COMET의 역량에 관한 발표를 포함할 예정입니다. Bio-Techne는 Leica Biosystems와의 파트너십도 강화하고 있으며, Leica BOND 플랫폼에서 RNAscope 분석을 시연하는 리셉션을 공동 주최합니다.
Bio-Techne (NASDAQ: TECH) a annoncé des avancées dans son portefeuille de biologie spatiale, mettant en avant la technologie RNAscope™ ISH et les plateformes Lunaphore COMET™. Ces innovations permettent la détection simultanée des biomarqueurs d’ARN et de protéines sur la même coupe tissulaire, rapprochant la recherche translationnelle des applications cliniques.
L’entreprise présentera ces technologies lors de la National Society of Histotechnology Convention (du 26 au 30 septembre), avec des présentations sur l’application de RNAscope à l’évaluation de la clonalité des cellules B et sur les capacités de COMET à profiler les malignités lymphoïdes en utilisant un panneau seqIF™ à 21 plex, et Bio-Techne renforce également son partenariat avec Leica Biosystems, en co-organisant une réception pour démontrer les tests RNAscope sur les plateformes Leica BOND.
Bio-Techne (NASDAQ: TECH) gab bekannt, dass Fortschritte im Bereich der Spatial-Biologie vorliegen, darunter die RNAscope™ ISH-Technologie und die Lunaphore COMET™-Plattformen. Diese Innovationen ermöglichen die gleichzeitige Detektion von RNA- und Protein-Biomarkern auf demselben Gewebeschnitt und verbinden translational Forschung mit klinischen Anwendungen.
Das Unternehmen wird diese Technologien auf der National Society of Histotechnology Convention (26.–30. September) vorstellen und Präsentationen zur Anwendung von RNAscope bei der Beurteilung der B-Zell-Klonalität sowie zu den Fähigkeiten von COMET bei der Profilierung lymphoider Malignome unter Nutzung eines 21‑plex seqIF™-Panels präsentieren. Bio-Techne stärkt auch seine Partnerschaft mit Leica Biosystems und veranstaltet gemeinsam einen Empfang, um RNAscope-Assays auf den Leica BOND-Plattformen zu demonstrieren.
Bio-Techne (NASDAQ: TECH) أعلنت عن تقدم في محفظة علم الأحياء الفضائية لديها، بما في ذلك تقنية RNAscope™ ISH ومنصات Lunaphore COMET™. تتيح هذه الابتكارات الكشف المتزامن عن علامات حيوية للـRNA والبروتين على نفس مقطع النسيج، مما يجسر بين أبحاث الترجمة والتطبيقات السريرية.
ستعرض الشركة هذه التقنيات في مؤتمر National Society of Histotechnology Convention (26-30 سبتمبر)، مع عروض حول تطبيق RNAscope في تقييم مزامن خلايا B والقدرات الخاصة بـ COMET في تعريف الأمراض اللمفاوية باستخدام لوحة seqIF™ بواقع 21-plex. كما تعزز Bio-Techne شراكتها مع Leica Biosystems، وتستضيف استقبالاً مشتركاً لعرض اختبارات RNAscope على منصات Leica BOND.
Bio-Techne (NASDAQ: TECH) 宣布其空间生物学产品组合的进展，其中包括 RNAscope™ ISH 技术 与 Lunaphore COMET™ 平台。这些创新使在同一组织切片上能够同时检测RNA和蛋白质生物标志物，桥接转化研究与临床应用。
公司将于 National Society of Histotechnology Convention（9月26–30日）展示这些技术，并对 RNAscope 在 B 细胞克隆性评估中的应用以及 COMET 在使用 21‑plex seqIF™ 面板对淋巴系统恶性肿瘤进行概况分析的能力进行演示。Bio-Techne 还在加强与 Leica Biosystems 的伙伴关系，联合主办一次招待会，演示在 Leica BOND 平台上的 RNAscope 检测。
- Development of advanced spatial biology tools for simultaneous RNA and protein detection
- Integration potential into diagnostic workflows, especially for limited tissue samples
- Partnership advancement with Leica Biosystems for platform compatibility
- Products are currently For Research Use Only, not approved for diagnostic procedures
- Analytical and performance characteristics for IGLL5 probe not yet established
Insights
Bio-Techne advances spatial biology technologies that could strengthen their position in the translational and clinical markets.
Bio-Techne has announced significant advancements in their spatial biology portfolio, specifically for their RNAscope™ ISH technology and the Lunaphore COMET™ platform. These innovations enable simultaneous detection of RNA and protein biomarkers on the same tissue section, creating a powerful bridge between translational research and potential clinical applications.
The technical capabilities highlighted are particularly noteworthy. RNAscope™ can detect clinically relevant biomarkers like viral markers, secreted proteins, point mutations, and chromosomal translocations within standard pathology workflows. Meanwhile, COMET™ offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, which accelerates spatial multiomic workflows.
The company is showcasing these technologies at the National Society of Histotechnology Convention with multiple presentations highlighting potential clinical applications. The studies presented include using RNAscope™ for B-cell clonality assessment and COMET™ for spatial profiling of lymphoid malignancies with a 21-plex seqIF™ panel.
These advancements position Bio-Techne to potentially capture more market share in the rapidly growing spatial biology sector, especially as these technologies demonstrate utility in diagnostic workflows where tissue samples are limited. While both technologies are currently labeled
Bio-Techne's continued partnership with Leica Biosystems for RNAscope assays on Leica BOND platforms further strengthens their distribution capabilities and market penetration potential in clinical and research laboratories that already use Leica equipment.
- RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section
- Technologies support spatial multiomic analysis and deeper insights for pathology workflows
- Research highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonality
RNAscope™ empowers pathologists and histologists to detect clinically relevant biomarkers—such as viral markers, secreted proteins, point mutations, and chromosomal translocations—within routine anatomic pathology workflows. COMET™ offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights.
Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™ for assessing B-cell clonality with IGLL5 detection, and COMET™ for spatial profiling of lymphoid malignancies using a 21-plex seqIF™ panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability.
Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26–30 in
Presentations include:
- RNAscope™ for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™ over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.)
- RNAscope™ of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™ for assessing B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. (Poster #6038, Sep. 30, 9:05–9:20 a.m.)
- seqIF™ Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. (Poster #6043)
Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Parker's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.
"We are thrilled by the progress we've made in advancing traditional in situ hybridization," said Dr. Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne. "By working hand-in-hand with our customers and learning from the exceptional speakers at NSH, we are creating innovative tools that bring us closer to unlocking the molecular drivers of disease and transforming patient care."
Disclaimer:
The RNAscope probe for IGLL5 is an Analyte Specific Reagent. Analytical and performance characteristics have not been established.
RNAscope and COMET are For Research Use Only. Not for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact:
Corporate Communications
media.relations@bio-techne.com
David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-advances-spatial-biology-solutions-bridging-translational-research-to-clinical-applications-302568115.html
SOURCE Bio-Techne Corporation
FAQ
What new technologies did Bio-Techne announce for spatial biology?
What are the key applications of Bio-Techne's RNAscope technology?
How does the COMET platform benefit research workflows?
When and where will Bio-Techne showcase these technologies?
Are Bio-Techne's new spatial biology tools approved for clinical diagnosis?
